miRNA | Previously reported in the literature | Ref | NGS Counts | Mean Fold change (2-ΔΔCt) (95% C.I.) | ||
---|---|---|---|---|---|---|
CTRL | DLB | AD | ||||
hsa-miR-21-5p | Down-regulated in serum-EVs from AD patients compared to controls | [20] | 14,337 | 1.49 (0.91–2.06) | 1.81 (0.67–2.96) | 0.29 (0.03–0.56) |
Up-regulated in serum-EVs from PD patients in comparison to AD | ||||||
Down-regulated in CSF from AD patients compared to control individuals | [42] | |||||
Down-regulated in plasma from PD patients compared to normal controls | [43] | |||||
hsa-miR-26a-5p | Deregulated in AD blood (different results in NGS and qPCR) | [44] | 27,896 | 1.88 (0.96–2.79) | 1.04 (0.54–1.53) | 0.8 (0.09–1.5) |
miR-26a is up-regulated in CSF from PD patients compared to controls | [21] | |||||
Up-regulated in blood from AD patients compared to controls | ||||||
Down-regulated in CSF from AD patients compared to controls | [19] | |||||
Down-regulated in serum from AD patients compared to healthy controls | [47] | |||||
Down-regulated in ALS blood compared to controls | [48] | |||||
hsa-let-7i-5p | Down-regulated in PD brains compared to controls | [49] | 15,170 | 1.43 (0.78–2.09) | 1.23 (0.05–1.75) | 0.41 (0.06–0.75) |
Increased expression in AD patients’ hippocampus | [50] | |||||
Up-regulated in CSF from AD compared to controls. | [42] | |||||
Down-regulated in ALS compared to controls | [48] | |||||
hsa-miR-126-3p | miR-126 is down-regulated in CSF-EXs from AD and PD patients vs controls | 37,418 | 2.23 (1.41–3.04) | 1.88 (0.66–3.1) | 0.89 (0.03–1.74) | |
Increased expression in the hippocampus of AD mouse model vs WT controls | [52] | |||||
hsa-miR-451a | Up-regulated in serum-EXs from MS patients compared to controls | [53] | 10,058 | 2.05 (1.21–2.88) | 1.84 (0.76–2.92) | 0.19 (0.05–0.33) |
Increased in plasma from vascular dementia patients compared to healthy controls | [54] | |||||
Decreased expression in CSF-EXs from AD compared to controls | [55] | |||||
Down-regulated in ALS compared to controls | [48] | |||||
hsa-miR-23a-3p | Up-regulated in brain tissue from AD patients | [50] | 6834 | 1.85 (1.24–2.45) | 1.17 (0.65–1.68) | 0.52 (0.06–0.97) |
miR-23a is down-regulated in serum samples from AD patients’ vs FTD and controls | [56] | |||||
Down-regulated in blood from MS patients compared to controls | [57] | |||||
Down-regulated in CSF from AD patients compared to control individuals | [42] | |||||
Reflect MS disease status in serum-EXs | [53] | |||||
Increased expression in brain tissue from AD patients compared to controls | [51] | |||||
Down-regulated in ALS blood compared to controls | [48] | |||||
hsa-let-7f-5p | Up-regulated in AD hippocampus compared to healthy controls | [50] | 191,299 | 1.29 (0.59–1.99) | 1.28 (0.23–2.34) | 1.05 (0.33–1.76) |
Up-regulated in AD serum compared to healthy controls | [58] | |||||
Down-regulated in blood from AD patients compared to controls | [45] | |||||
Down-regulated in ALS blood /plasma compared to controls | ||||||
hsa-miR-409-3p | Down-regulated in the prefrontal cortex of AD patients | [50] | 5236 | 1.48 (0.05–3.01) | 1.46 (0.12–2.79) | 1.35 (0.19–2.52) |
Down-regulated in CSF from PD patients compared to controls | [20] | |||||
Up-regulated in CSF-EXs from PD patients compared to AD and control EXs | ||||||
Up-regulated in serum-EXs from MS patients compared to controls | [53] | |||||
Down-regulated in plasma from vascular dementia patients compared to controls | [54] | |||||
hsa-miR-92a-3p | Down-regulated expression in serum from PD patients compared to controls | [61] | 30,066 | 1.89 (0.42–3.35) | 1.22 (0.54–1.89) | 1.38 (− 0.29–3.06) |
Differentially expressed in PD and Huntington patients’ brain | [62] | |||||
Up-regulated in CSF from AD patients compared to control individuals | [42] | |||||
Down-regulated in the serum samples of AD patients’ vs MCI subjects | [63] | |||||
Differentially expressed in AD and MCI | [64] | |||||
hsa-let-7b-5p | Let-7b miRNA is up-regulated in AD patients’ brain | [51] | 107,394 | 1.98 (0.07–3.89) | 0.81 (0.39–1.23) | 2.097 (0.58–3.61) |
Let-7b is down-regulated in the white matter of AD patients | [65] | |||||
Increased amounts of let-7b in CSF from AD patients | [66] | |||||
Differentially expressed in AD in comparison to controls | [64] | |||||
hsa-miR-151a-3p | Up-regulated in AD blood compared to controls | [44] | 5798 | 2.04 (− 0.13–4.22) | 0.98 (0.34–1.63) | 0.70 (− 0.09–1.5) |
Up-regulated in blood from AD patients compared to controls | [45] | |||||
Differentially expressed in AD in comparison to controls | [64] | |||||
hsa-miR-24-3p | miR-24 is up-regulated in serum and plasma of MSA compared to PD patients | [67] | 10,896 | 1.5 (0.68–2.33) | 1.49 (0.28–2.69) | 25.21 (3.11–47.31) |
Dow-regulated in plasma-EXs from AD patients compared to controls | [22] | |||||
miR-24 is deregulated in CSF from AD patients | [68] | |||||
Decreased expression in AD-CSF compared to controls | ||||||
miR-24 expression is decreased in CSF from PD patients compared to controls | [16] | |||||
Differently expressed in blood and CSF in AD and FTD patients | [70] | |||||
hsa-miR-143-3p | miR-143 is up-regulated in AD brain patients | [51] | 17,380 | 5.85 (− 2.88–14.6) | 1.22 (− 0.11–2.56) | 2.42 (− 1.28–6.11) |
Down-regulated in CSF from ALS patients compared to controls | [71] | |||||
Increased expression in serum-EXs of AD patients vs healthy controls | [23] | |||||
Down-regulated in serum from AD patients | [72] | |||||
Up-regulated in CSF from AD and dementia patients compared to controls | [42] | |||||
Up-regulated in brain of PD mouse model | [73] | |||||
Increased expression in serum ALS compared to controls | [74] | |||||
hsa-miR-423-5p | Under-represented in the cortex of AD patients | 8928 | 1.99 (0.52–3.46) | 1.23 (0.43–2.04) | 8.04 (2.02–14.06) | |
Increased expression in CSF from AD and dementia patients vs controls | [42] | |||||
Down-regulated expression in PD putamen tissue | [73] | |||||
Differentially expressed in AD blood compared to healthy controls | [64] | |||||
Down-regulated in plasma from PD patients compared to normal controls | [43] | |||||
Up-regulated in CSF from AD patients compared to controls | [51] | |||||
Low expression in CSF from PD patients | [75] | |||||
hsa-miR-183-5p | In serum, associated to neurofibrillary tangles score in AD patients | [20] | 3820 | 1.18 (0.63–1.73) | 0.79 (0.15–1.44) | 15.77 (0.84–30.7) |
Differentially expressed in AD and other types of dementia patients vs controls | [42] | |||||
Down-regulated in peripheral blood from ALS patients | [48] | |||||
Decreased expression is associated to PD | [76] |